Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical trial design for target specific anticancer agents.

Ronald Hoekstra1, Jaap Verweij, Ferry A L M Eskens

  • 1Department of Medical Oncology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. R.Hoekstra.1@erasmusmc.nl

Investigational New Drugs
|August 2, 2003
PubMed
Summary

New targeted anticancer agents are cytostatic, not cytotoxic, requiring adapted clinical trial designs. Phase I and II studies need modification to accurately assess efficacy and safety of these novel therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Challenges and Potential Solutions to Advance Global Cancer Drug Development.

Therapeutic innovation & regulatory science·2026
Same author

Delayed gastric emptying after pancreatic cancer surgery impacts time to start of adjuvant treatment but not overall survival: a post-hoc analysis of the PREOPANC-1 and -2 trials.

The British journal of surgery·2025
Same author

REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer.

Nature communications·2025
Same author

Empowering effective biomarker-driven precision oncology: A call to action.

European journal of cancer (Oxford, England : 1990)·2024
Same author

Chemotherapy-Induced Peripheral Neuropathy in Patients With Gastroesophageal Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN·2024
Same author

The OCT2/MATE1 Interaction Between Trifluridine, Metformin and Cimetidine: A Crossover Pharmacokinetic Study.

Clinical pharmacokinetics·2024

Area of Science:

  • Oncology
  • Clinical Trial Design
  • Pharmacology

Background:

  • Numerous novel anticancer agents target specific cellular processes involved in cancer.
  • These agents primarily exhibit cytostatic (growth inhibition) rather than cytotoxic (cell death) effects.
  • Target-specific agents are anticipated to have improved toxicity profiles compared to traditional chemotherapies.

Purpose of the Study:

  • To discuss challenges in developing clinical trials for new target-specific anticancer agents.
  • To propose adaptations for Phase I and II study designs based on the cytostatic nature of these drugs.
  • To integrate these adaptations with existing concepts for cytotoxic and cytostatic agent trial design.

Main Methods:

  • Review of current practices in Phase I and II clinical trial design for anticancer agents.

Related Experiment Videos

  • Analysis of the impact of cytostatic mechanisms on toxicity and efficacy assessment.
  • Conceptual framework development for adapting trial designs for target-specific agents.

    • Main Results:

    • Current Phase I/II trial designs, focused on dose-limiting toxicity and tumor regression, may be inadequate for cytostatic agents.
    • Adaptations are necessary to appropriately evaluate the efficacy (growth inhibition) and safety of target-specific therapies.
    • Distinguishing between cytotoxic and cytostatic agents, while useful, can be an oversimplification requiring nuanced trial approaches.

    Conclusions:

    • Clinical trial designs for novel anticancer agents must evolve to accommodate their cytostatic mechanisms and favorable toxicity profiles.
    • Modified Phase I/II studies are crucial for accurately assessing the therapeutic potential of target-specific anticancer drugs.
    • Future research should focus on refining trial methodologies to better suit the unique characteristics of emerging cancer therapies.